Abstract | BACKGROUND AND PURPOSE: EXPERIMENTAL APPROACH: KEY RESULTS: Treatment with ODN/ Pam2 caused ~75% reduction in lung Sendai virus burden 5 days after challenge. The reduction in acute lung virus burden was associated with marked reductions 49 days after viral challenge in eosinophilic and lymphocytic lung inflammation, airway mucous metaplasia, lumenal mucus occlusion and hyperresponsiveness to methacholine. Mechanistically, ODN/ Pam2 treatment attenuated the chronic asthma phenotype by suppressing IL-33 production by type 2 pneumocytes, both by reducing the severity of acute infection and by down-regulating Type 2 (allergic) inflammation. CONCLUSION AND IMPLICATIONS: These data suggest that treatment of susceptible human hosts with aerosolized ODN and Pam2 at the time of a respiratory viral infection might attenuate the severity of the acute infection and reduce initiation, exacerbation and progression of asthma.
|
Authors | David L Goldblatt, Jose R Flores, Gabriella Valverde Ha, Ana M Jaramillo, Sofya Tkachman, Carson T Kirkpatrick, Shradha Wali, Belinda Hernandez, David E Ost, Brenton L Scott, Jichao Chen, Scott E Evans, Michael J Tuvim, Burton F Dickey |
Journal | British journal of pharmacology
(Br J Pharmacol)
Vol. 177
Issue 10
Pg. 2256-2273
(05 2020)
ISSN: 1476-5381 [Electronic] England |
PMID | 31968123
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2020 The British Pharmacological Society. |
Topics |
- Animals
- Asthma
(drug therapy, prevention & control)
- Hypersensitivity
- Lung
- Mice
- Mice, Inbred BALB C
- Pneumonia
- Virus Diseases
|